Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0516 in Metastatic Prostate Cancer
2024-520026-11-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of AZD0516 in prostate cancer (PCa) (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability (Part A dose escalation), PSA50 response rate (Parts B and C) and 1 more. Planned start Dec 2025; status: authorised.
02
Drugs
AZD0516
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-520026-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520026-11-00.